In Brief: Bristol-Myers Squibb v. Shalala
Bristol-Myers Squibb v. Shalala: Third of three cases brought by Bristol on bulk bleomycin sulfate dismissed July 21 by D.C. federal court Judge Stanley Harris. Bristol had challenged FDA's decision that it is authorized to approve AADAs for generic bleomycin sulfate products made from a bulk substance that does not conform to the bulk substance used to make Blenoxane. The company also asserted that FDA should not approve the new bulk substance before producing a monograph ("The Pink Sheet" April 10, T&G-22). The court ruled that Bristol "lacks constitutional standing to challenge FDA's position until the agency actually approves an application for the bulk substance," according to FDA...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth